SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

March 04, 2014 16:00 ET

Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences

Data to Highlight the Mechanism of Action and Therapeutic Effects of the Company's PS-Targeting Antibodies in Oncology and Anti-Viral Indications

TUSTIN, CA--(Marketwired - Mar 4, 2014) -  Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014. Bavituximab, the company's lead immunotherapy candidate, is advancing in a Phase III SUNRISE trial for the treatment of second-line non-small cell lung cancer.


Plenary Talk: Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor-Specific Immunity
Presenter: Xianming Huang, Ph.D., Assistant Professor, Hamon Center for Therapeutic Oncology, Pharmacology, Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center, Dallas, Texas
Date: Wednesday, March 12, 2014
Time: 2:30 P.M. - 4:30 P.M. Pacific Time
Workshop: #3: Immune Suppressive Myeloid Cells
Location: MacDonald DEF Room, Fairmont Chateau Whistler, Whistler, British Columbia, Canada

Title: Phosphatidylserine Targeting Antibodies Enhance the Activity of Immune Checkpoint Inhibitors in Tumors
Presenter: Bruce Freimark, Ph.D., Director of Pre-Clinical Research Oncology, Peregrine Pharmaceuticals
Poster: Poster Session 1 - Poster 1029
Date: Monday, March 10, 2014
Viewing: 1:00 P.M. - 10:00 P.M. Pacific Time
Presentation: 7:30 P.M. - 10:00 P.M. Pacific Time
Location: Frontenac Ballroom and Foyer - Fairmont Chateau Whistler, Whistler, British Columbia, Canada

Title: Phosphatidylserine-Targeting Antibody Triggers B-Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a Potent Inhibitor of HIV-1 In Vitro
Presenter: Cyril Empig, Ph.D., Associate Director, Pre-Clinical Research Infectious Disease, Peregrine Pharmaceuticals
Poster: Poster Session 3 - Poster 3020
Date: Wednesday, March 12, 2014
Viewing: 1:00 P.M. - 10:00 P.M. Mountain Time
Presentation: 7:30 P.M. - 10:00 P.M. Mountain Time
Location: Mezzanine 2 - Fairmont Banff Springs, Alberta, Canada

About Bavituximab: A Targeted Immunotherapy
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor. These data detailing the immune-stimulatory mechanism of action of PS-targeting antibodies, such as the company's lead drug candidate bavituximab, are the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) peer-reviewed journal, Cancer Immunology Research. Bavituximab is currently being evaluated in several solid tumor indications, including non-small cell lung cancer, breast cancer, liver cancer and rectal cancer with a trial in advanced melanoma anticipated to initiate in the near future.

About Keystone Symposia
Keystone Symposia serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab while seeking a partner to further advance its novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at

Contact Information

  • Contact:

    Christopher Keenan or Jay Carlson
    Peregrine Pharmaceuticals
    (800) 987-8256